Finch Therapeutics Group, Inc. (FNCH)
USD 12.74
(-0.08%)
USD 12.74
(-0.08%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5 Million USD | 126.75% |
| 2022 | -18.69 Million USD | 85.33% |
| 2021 | -127.46 Million USD | -30.2% |
| 2020 | -97.9 Million USD | -196.97% |
| 2019 | 100.96 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 8.8 Million USD | 75.95% |
| 2024 Q2 | 12.95 Million USD | 47.19% |
| 2023 Q1 | -5.54 Million USD | 70.32% |
| 2023 FY | 5 Million USD | 126.75% |
| 2023 Q4 | 5 Million USD | 150.98% |
| 2023 Q3 | 1.99 Million USD | 166.28% |
| 2023 Q2 | -3 Million USD | 45.81% |
| 2022 Q2 | -49.43 Million USD | 51.15% |
| 2022 FY | -18.69 Million USD | 85.33% |
| 2022 Q1 | -101.18 Million USD | 20.61% |
| 2022 Q4 | -18.69 Million USD | 43.24% |
| 2022 Q3 | -32.94 Million USD | 33.36% |
| 2021 Q1 | -191.21 Million USD | -95.31% |
| 2021 FY | -127.46 Million USD | -30.2% |
| 2021 Q4 | -127.46 Million USD | 14.57% |
| 2021 Q3 | -149.2 Million USD | 11.26% |
| 2021 Q2 | -168.13 Million USD | 12.07% |
| 2020 Q1 | 42.18 Million USD | 0.0% |
| 2020 Q4 | -97.9 Million USD | 0.0% |
| 2020 FY | -97.9 Million USD | -196.97% |
| 2019 FY | 100.96 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | -175.422% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 231.114% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -298.884% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 84.473% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 632.694% |
| Better Therapeutics, Inc. | -860 Thousand USD | 681.628% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 121.03% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -1422.952% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -9.453% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 185.901% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -56.41% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | -57.957% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 96.268% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -2692.074% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 59.46% |
| Molecular Templates, Inc. | 707 Thousand USD | -607.496% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -1040.853% |
| NexImmune, Inc. | -3.13 Million USD | 259.623% |
| Orgenesis Inc. | 21.78 Million USD | 77.038% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -91.208% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 1004517.671% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 206.185% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 4115.252% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 95.488% |
| Statera Biopharma, Inc. | 14.41 Million USD | 65.303% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 165.85% |
| Trevena, Inc. | 2.25 Million USD | -121.523% |
| Vaxxinity, Inc. | 10.13 Million USD | 50.632% |
| Vaccinex, Inc. | -1.28 Million USD | 488.354% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -1352.187% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 62.218% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -6850.891% |